Castle Biosciences, Inc. (CSTL)

In February 2026, the stock traded flat awaiting Q4 2025 earnings, experiencing recent price pressure. In January 2026, shares rose following an analyst endorsement from KeyBanc and stronger-than-expected preliminary financial results for 2025. In December 2025, the company saw small positive price moves associated with equity grants and favorable publications. In November 2025, Castle Biosciences reported its Q3 2025 earnings, exceeding estimates and raising full-year revenue guidance, also announcing the launch of AdvanceAD-Tx™. In April 2025, a Novitas local coverage determination impacted Q3 revenue, along with the discontinuation of IDgenetix.

There is no explicit information indicating significant demand seasonality for Castle Biosciences, Inc.'s products and services. The company has reported strong and accelerating core test volume growth, particularly for its DecisionDx-Melanoma and TissueCypher Barrett's Esophagus assays.

Castle Biosciences, Inc. is a commercial-stage molecular diagnostics company focused on improving health through innovative tests. The company develops and markets gene expression profile tests, primarily for dermatological cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. Key products include DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, MyPath Melanoma, TissueCypher, and AdvanceAD-Tx™. Approximately 88% of the company's revenue is derived from dermatologic tests.

Castle Biosciences, Inc. is headquartered in Friendswood, Texas. Its laboratory operations are located in Phoenix, Arizona, and Pittsburgh, Pennsylvania.

Castle Biosciences has maintained a positive brand reputation, receiving the Greater Pittsburgh Top Workplaces award in 2025. The company was included in Newsweek's 2025 America's Greatest Companies list and featured in a USA TODAY Skin Health Campaign article. An expert consensus paper endorsed the company's DecisionDx-Melanoma test, and multiple favorable clinical and outcomes publications for DecisionDx and TissueCypher were released.

Castle Biosciences, Inc. has a high degree of institutional ownership, exceeding 90%. Major institutional owners and shareholders include BlackRock, Inc., Vanguard Group Inc., Principal Financial Group Inc., Portolan Capital Management, LLC., Dimensional Fund Advisors Lp., Nuveen, LLC., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, PSBMX - SmallCap Fund (fka SmallCap Blend Fund) R-3, Braidwell Lp., and FSAKX - Strategic Advisers U.S. Total Stock Fund.